Sickle Cell Treatment in Halted Trial Not Linked to Blood Cancer

Last month, a trial of a gene therapy for sickle cell disease (SCD) from Bluebird Bio, Inc. was halted after two study participants developed blood cancer. New updates from the research team suggest little evidence that the gene therapy, BB305, caused the development of acute myeloid leukemia (AML) in one patient. “We see no significant … Continue reading Sickle Cell Treatment in Halted Trial Not Linked to Blood Cancer